查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596221

呼吸道感染疾病藥物市場：按藥物、適應症和分銷管道分類 - 全球預測 2025-2030 年

Respiratory Tract Infection Therapeutic Market by Drugs (Antibiotics, Cough Suppressants, Nasal Decongestants), Disease Indication (Lower Respiratory Tract Infection, Upper Respiratory Tract Infection), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，呼吸道感染疾病藥物市值為453.3億美元，預計到2024年將達到488.3億美元，複合年成長率為7.80%，預計到2030年將達到767億美元。

呼吸道感染疾病治療市場包括多種上呼吸道和下呼吸道感染疾病的治療方法，例如流感、支氣管炎和肺炎。這些治療方法包括抗病毒藥物和抗生素、新生技藥品和個人化醫療方法。全球呼吸系統疾病的高發病率和老年人口的不斷成長推動了需求的成長，老年人口特別容易受到這些感染疾病的影響。都市化進程的加速、污染和氣候變遷進一步加劇了感染疾病的傳播，並增加了對有效治療方法的需求。醫院、診所和居家醫療機構是該市場的主要最終用戶，這凸顯了可獲得且負擔得起的醫療服務的重要性。監管核准、成本控制（特別是在發展中地區）和抗藥性菌株的出現是影響該行業的主要成長要素。遠端醫療和數位醫療的出現為患者參與和治療依從性提供了新的方式和潛在的機會。 COVID-19 大流行凸顯了快速診斷和治療反應的重要性，並刺激了呼吸治療領域的創新。對生技藥品和疫苗開發的投資，以及了解呼吸系統健康中微生物組的研究，提供了一條有利可圖的途徑，可能會導致新型益生菌和微生物組調節療法。然而，嚴格的監管途徑、高昂的研發成本以及醫療基礎設施的區域差異等挑戰構成了重大障礙。此外，學名藥的競爭和專利到期威脅市場盈利。創新的關鍵領域包括開發基於奈米技術的標靶治療輸送系統，以及探索人工智慧和巨量資料以預測感染趨勢和個人化治療的模型。為了跟上這些動態，必須策略性地專注於製藥公司和高科技公司之間的夥伴關係，以解決未滿足的臨床需求，並推動使產品在競爭格局中脫穎而出。

主要市場統計
基準年[2023] 453.3億美元
預測年份 [2024] 488.3億美元
預測年份 [2030] 767億美元
複合年成長率（%） 7.80%

市場動態：快速發展的呼吸道感染疾病治療市場的關鍵市場洞察

供需的動態交互作用正在改變呼吸道感染疾病藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 氣喘和呼吸道感染疾病的報告增加
    • 生活方式的改變和老年人口的增加
    • 加速學名藥和生物相似藥的開發
  • 市場限制因素
    • 季節性適應症和測試
  • 市場機會
    • 藥物開發和商業化投資
    • 藥物輸送系統的技術開發
  • 市場挑戰
    • 抗菌素抗藥性的出現

波特五力戰略工具駕馭感染疾病藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解呼吸道感染疾病藥物市場的外部影響

外部宏觀環境因素在塑造呼吸道感染疾病治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解呼吸道感染疾病治療藥物市場的競爭狀況

呼吸道感染疾病治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣呼吸道感染疾病藥物市場供應商的績效評估

FPNV 定位矩陣是評估呼吸道感染疾病治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了呼吸道感染疾病藥物市場的成功之路

對於尋求加強其在全球市場的影響力的公司來說，對感染疾病藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 氣喘和呼吸道感染疾病的報告增加
      • 生活方式的改變與衰老
      • 促進學名藥和生物相似藥的開發
    • 抑制因素
      • 季節性徵兆和檢查
    • 機會
      • 藥物開發和商業化投資
      • 藥物輸送系統的技術開發
    • 任務
      • 抗菌素抗藥性的出現
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 呼吸道感染疾病藥品市場（依藥品）

  • 抗生素
  • 止咳藥
  • 鼻減充血劑
  • 非類固醇消炎劑

第7章 呼吸道感染疾病治療藥物市場：依疾病適應症

  • 下呼吸道感染疾病
  • 上呼吸道感染疾病

第8章 呼吸道感染疾病藥物市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章美洲呼吸道感染疾病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太呼吸道感染疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲呼吸道感染疾病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • WG Critical Care, LLC by PharmaSphere Ltd.
Product Code: MRR-035AB9C0DAC8

The Respiratory Tract Infection Therapeutic Market was valued at USD 45.33 billion in 2023, expected to reach USD 48.83 billion in 2024, and is projected to grow at a CAGR of 7.80%, to USD 76.70 billion by 2030.

The respiratory tract infection therapeutic market encompasses a variety of treatments targeting infections in the upper and lower respiratory tracts, such as influenza, bronchitis, and pneumonia. These interventions range from antiviral and antibiotic medications to emerging biologics and personalized medicine approaches. The demand is driven by the high prevalence of respiratory diseases worldwide and the growing elderly population, who are particularly susceptible to such infections. Increased urbanization, pollution, and climate change further escalate incidences, thus boosting the necessity for effective therapies. Hospitals, clinics, and home care settings represent the key end-users within this market, underscoring the importance of accessible and affordable treatments. Regulatory approvals, cost management (especially in developing regions), and the emergence of drug-resistant strains are primary growth factors influencing this space. The advent of telemedicine and digital health represents potential opportunities, offering new modalities for patient engagement and treatment compliance. The COVID-19 pandemic has underscored the importance of rapid diagnostic and therapeutic responses, fostering innovation in respiratory therapeutics. Investment in biologics and vaccine development presents a lucrative avenue, as does research into understanding microbiomes in respiratory health, which could lead to novel probiotic or microbiome-modulating therapies. However, challenges such as stringent regulatory pathways, high R&D costs, and varying healthcare infrastructure across geographies pose significant barriers. Moreover, generic competition and patent expirations threaten market profitability. Key areas of innovation include the development of nanotechnology-based delivery systems for targeted treatment and the exploration of AI and big data for predictive modeling in infection trends and treatment personalization. Keeping abreast of these dynamics necessitates a strategic focus on partnerships between pharmaceutical companies and tech firms, fostering advancements that address unmet clinical needs and differentiate products in a competitive landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 45.33 billion
Estimated Year [2024] USD 48.83 billion
Forecast Year [2030] USD 76.70 billion
CAGR (%) 7.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Tract Infection Therapeutic Market

The Respiratory Tract Infection Therapeutic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased reports cases of asthma and respiratory tract infection
    • Changing Lifestyle and geriatric population
    • Increase development of generic drugs and biosimilars in the space
  • Market Restraints
    • Seasonal indications and inspections
  • Market Opportunities
    • Investment in drug development and commercialization
    • Technology development in drug delivery systems
  • Market Challenges
    • Emergence of antimicrobial resistance

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Tract Infection Therapeutic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Tract Infection Therapeutic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Tract Infection Therapeutic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Tract Infection Therapeutic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Tract Infection Therapeutic Market

A detailed market share analysis in the Respiratory Tract Infection Therapeutic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Tract Infection Therapeutic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Tract Infection Therapeutic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Tract Infection Therapeutic Market

A strategic analysis of the Respiratory Tract Infection Therapeutic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Tract Infection Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Piramal Enterprises Ltd., Teva Pharmaceutical Industries Ltd., and WG Critical Care, LLC by PharmaSphere Ltd..

Market Segmentation & Coverage

This research report categorizes the Respiratory Tract Infection Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drugs, market is studied across Antibiotics, Cough Suppressants, Nasal Decongestants, and Non-Steroidal Anti-Inflammatory Drugs.
  • Based on Disease Indication, market is studied across Lower Respiratory Tract Infection and Upper Respiratory Tract Infection.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased reports cases of asthma and respiratory tract infection
      • 5.1.1.2. Changing Lifestyle and geriatric population
      • 5.1.1.3. Increase development of generic drugs and biosimilars in the space
    • 5.1.2. Restraints
      • 5.1.2.1. Seasonal indications and inspections
    • 5.1.3. Opportunities
      • 5.1.3.1. Investment in drug development and commercialization
      • 5.1.3.2. Technology development in drug delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Emergence of antimicrobial resistance
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Respiratory Tract Infection Therapeutic Market, by Drugs

  • 6.1. Introduction
  • 6.2. Antibiotics
  • 6.3. Cough Suppressants
  • 6.4. Nasal Decongestants
  • 6.5. Non-Steroidal Anti-Inflammatory Drugs

7. Respiratory Tract Infection Therapeutic Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Lower Respiratory Tract Infection
  • 7.3. Upper Respiratory Tract Infection

8. Respiratory Tract Infection Therapeutic Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Respiratory Tract Infection Therapeutic Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Respiratory Tract Infection Therapeutic Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Apotex Inc.
  • 3. AstraZeneca PLC
  • 4. Aurobindo Pharma Limited
  • 5. Bristol Myers Squibb Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Fresenius SE & Co. KGaA
  • 8. GlaxoSmithKline PLC
  • 9. Hikma Pharmaceuticals PLC
  • 10. Merck & Co., Inc.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Piramal Enterprises Ltd.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. WG Critical Care, LLC by PharmaSphere Ltd.

LIST OF FIGURES

  • FIGURE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RESEARCH PROCESS
  • FIGURE 2. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023